Study on Nusinersen (BIIB058) – Devote trial: Show greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA)

Biogen announced updates to the SPINRAZA (nusinersen) clinical development program including the initiation of a new global clinical trial, DEVOTE.

New study, DEVOTE, to evaluate if SPINRAZA can offer even greater efficacy in treating SMA
Building on the demonstrated long-term safety profile and proven efficacy of SPINRAZA in a broad range of patients, the DEVOTE trial will examine the potential for even greater efficacy, as well as the safety and tolerability of SPINRAZA, when administered at a higher dose. The trial is a Phase 2/3 randomized, controlled dose-escalating study that will be conducted at 50 sites around the world with a projected enrollment of 126 individuals with SMA of all ages, including adults.

Clinical Trial
NCT04089566

Publicerat av

Liz

Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg

3 reaktioner till “Study on Nusinersen (BIIB058) – Devote trial: Show greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA)”

Kommentarer inaktiverade.